Patents by Inventor David Curiel

David Curiel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10709745
    Abstract: In some embodiments, methods of killing tumor cells are provided. The methods may include contacting the tumor cell with a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective element and/or a capsid protein that binds a tumor-specific cell surface molecule. In another embodiment, methods of treating cancer are provided. The methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: July 14, 2020
    Assignees: CITY OF HOPE, UNIVERSITY OF ALABAMA AT BIRMINGHAM, UNIVERSITY OF CHICAGO
    Inventors: Karen S. Aboody, Alexander J. Annala, David Curiel, Maciej Lesniak
  • Publication number: 20190275093
    Abstract: In some embodiments, methods of killing tumor cells are provided. The methods may include contacting the tumor cell with a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective element and/or a capsid protein that binds a tumor-specific cell surface molecule. In another embodiment, methods of treating cancer are provided. The methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule.
    Type: Application
    Filed: March 21, 2019
    Publication date: September 12, 2019
    Inventors: Karen S. ABOODY, Alexander J. ANNALA, David CURIEL, Maciej LESNIAK
  • Patent number: 10391183
    Abstract: A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: August 27, 2019
    Assignees: The UAB Research Foundation, The Board of Regents of the University of Texas System
    Inventors: Juan Fueyo-Margareto, Candelaria Gomez-Manzano, David Curiel
  • Publication number: 20190201551
    Abstract: An adenovirus vector comprising: a pulmonary targeting coding sequence, CRISPR components such as a Cas9 coding sequence, and a guideRNA coding sequence which can be used for gene therapy. The adenovirus can be a gorilla adenovirus, and can include a pulmonary cell targeting sequence such as an MBP targeting ligand coding sequence. The adenovirus can be targeted to pulmonary epithelium with a vascular specific promoter and integrin targeting peptides incorporated into a viral knob. The adenovirus can be used to introduce serum proteins via the pulmonary epithelium. Hemophilia can be treated by adenoviral introduction of factor VIII or factor IX.
    Type: Application
    Filed: May 23, 2017
    Publication date: July 4, 2019
    Applicant: Washington University
    Inventor: David CURIEL
  • Patent number: 10238699
    Abstract: In some embodiments, methods of killing tumor cells are provided. The methods may include contacting the tumor cell with a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective element and/or a capsid protein that binds a tumor-specific cell surface molecule. In another embodiment, methods of treating cancer are provided. The methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: March 26, 2019
    Assignees: CITY OF HOPE, UNIVERSITY OF CHICAGO, UNIVERSITY OF ALABAMA AT BIRMINGHAM
    Inventors: Karen S. Aboody, Alexander J. Annala, David Curiel, Maciej Lesniak
  • Publication number: 20180051301
    Abstract: Disclosed are compositions and methods relating to the cardiac conduction system. Compositions, methods for converting cardiac tissue to an induced-sinoatrial node, and methods for treating sinus node dysfunction (SND) in an individual in need thereof are disclosed. Also disclosed are compositions and methods for evaluating virally-transduced cardiac tissue.
    Type: Application
    Filed: March 2, 2016
    Publication date: February 22, 2018
    Inventors: Stacey Rentschler, Igor Efimov, David Curiel
  • Publication number: 20170159072
    Abstract: Disclosed are adenovirus vectors comprising a ROBO4 enhancer/promoter operatively linked to a transgene. Also disclosed are adenovirus vectors comprising a chimeric AD5-T4 phage fibritin shaft, a trimerization domain displaying a myeloid cell-binding peptide (MBP), and a ROBO4 enhancer promoter operatively linked to a transgene. Also disclosed are methods of expressing a transgene in an endothelial cell in vivo, comprising administering to a mammal an adenovirus comprising a ROBO4 enhancer/promoter operatively linked to a transgene. Also disclosed are uses of the adenoviral vectors, including mobilization of granulocytes, monocytes and lymphocytes from bone marrow, mobilization of cancer cells in vivo, selective targeting of endothelial cells, and cancer treatment methods.
    Type: Application
    Filed: December 11, 2015
    Publication date: June 8, 2017
    Applicant: Washington University
    Inventors: Jefferey Arbeit, David Curiel
  • Publication number: 20170044269
    Abstract: Polypeptides are disclosed comprising, in N-terminal-to-C-terminal order: an N-terminal segment of Ad5 fiber tail sequence; at least 2 pseudorepeats of an Ad5 fiber shaft domain sequence; a portion of a third Ad5 fiber shaft domain sequence; a carboxy-terminal segment of a 14 fibritin bacteriophage trimerization domain sequence; a linker sequence; and a camelid single chain antibody sequence. A camelid single chain antibody sequence can be against a human carcinoembryonic antigen. Also disclosed are nucleic acids encoding these polypeptides, and adenovirus vectors comprising the polypeptides. Methods are disclosed for treating a neoplastic disease. These methods can comprise administering an adenovirus vector comprising a disclosed polypeptide. Also disclosed are methods of targeting a vector to CEA-expressing cells. These methods comprise administering an adenovirus vector comprising a disclosed polypeptide.
    Type: Application
    Filed: October 18, 2016
    Publication date: February 16, 2017
    Inventors: David Curiel, Sergey Kaliberov
  • Publication number: 20160317591
    Abstract: In some embodiments, methods of killing tumor cells are provided. The methods may include contacting the tumor cell with a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective element and/or a capsid protein that binds a tumor-specific cell surface molecule. In another embodiment, methods of treating cancer are provided. The methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule.
    Type: Application
    Filed: September 11, 2015
    Publication date: November 3, 2016
    Inventors: Karen S. ABOODY, Alexander J. ANNALA, David CURIEL, Maciej LESNIAK
  • Publication number: 20160145643
    Abstract: Disclosed are adenovirus vectors comprising a ROBO4 enhancer/promoter operatively linked to a transgene. Also disclosed are adenovirus vectors comprising a chimeric AD5-T4 phage fibritin shaft, a trimerization domain displaying a myeloid cell-binding peptide (MBP), and a ROBO4 enhancer promoter operatively linked to a transgene. Also disclosed are methods of expressing a transgene in an endothelial cell in vivo, comprising administering to a mammal an adenovirus comprising a ROBO4 enhancer/promoter operatively linked to a transgene. Also disclosed are uses of the adenoviral vectors, including mobilization of granulocytes, monocytes and lymphocytes from bone marrow, mobilization of cancer cells in vivo, selective targeting of endothelial cells, and cancer treatment methods.
    Type: Application
    Filed: December 11, 2015
    Publication date: May 26, 2016
    Applicant: Washington University
    Inventors: Jefferey Arbeit, David Curiel
  • Publication number: 20140227226
    Abstract: A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.
    Type: Application
    Filed: January 6, 2014
    Publication date: August 14, 2014
    Applicants: The UAB Research Foundation, The Board of Regents of the University of Texas System
    Inventors: Juan FUEYO-MARGARETO, Candelaria GOMEZ-MANZANO, David CURIEL
  • Publication number: 20060275262
    Abstract: The present invention provides for methods and compositions for translation of a viral vector both in vitro and in vivo. Specifically, the present invention pertains to a translational control element placed in a vector to cause a selective translation of a viral vector.
    Type: Application
    Filed: October 28, 2005
    Publication date: December 7, 2006
    Inventors: James Mathis, Arrigo DeBenedetti, David Curiel
  • Publication number: 20060110324
    Abstract: Human anti-epidermal growth factor receptor (EGFR) single-chain antibodies (scFvs) were isolated from a human IgM phage display library using purified epidermal growth factor receptor as antigen. Two isolates with different amino acid sequences were identified by ELISA as epidermal growth factor receptor-specific. The scFvs bind to the full length epidermal growth factor receptor and the truncated and/or mutated epidermal growth factor receptor on human cells. These anti-EGFR-scFvs are useful as therapeutic and/or diagnostic agents.
    Type: Application
    Filed: December 23, 2005
    Publication date: May 25, 2006
    Inventors: Kevin Raisch, David Curiel, James Bonner
  • Publication number: 20050095231
    Abstract: The utility of adenovirus vectors (Ad) for gene therapy is restricted by their inability to selectively transduce disease-affected tissues. This limitation may be overcome by the derivation of vectors capable of interacting with receptors specifically expressed in the target tissue. Previous attempts to alter Ad tropism by genetic modification of the Ad fiber have had limited success due to structural conflicts between the fiber and the targeting ligand. The present invention presents a strategy to derive an Ad vector with enhanced targeting potential by a radical replacement of the fiber protein in the Ad capsid with a chimeric molecule containing a heterologous trimerization motif and a stabilized scFv ligand.
    Type: Application
    Filed: September 17, 2004
    Publication date: May 5, 2005
    Inventors: David Curiel, Nikolay Korokhov